KRX Bio Technology Transfer Index

Voronoi is targeting presentation of updated VRN110755 (VRN11) clinical data at the IASLC World Conference on Lung Cancer 2026, scheduled for September 12–15.

Daewoong Pharmaceutical scheduled an extraordinary general meeting for 9 September 2026 to re-elect Kwon Soon-yong as an independent director who will serve on the audit committee.

Voronoi’s 24-subject Phase 1 food-effect and proton-pump-inhibitor pharmacokinetic study of VRN101099 (VRN10) has an estimated primary-completion date of September 1, 2026.

AprilBio said it plans to hold its first R&D Day in late August to early September to present pipeline development, platform strategy, and the planned use of newly raised capital.

Yuhan Corp is due to file its H1 2026 interim report by August 14, 2026, creating the next formal earnings and Lazcluze-royalty disclosure catalyst.

Oscotec's H1 2026 semiannual report, covering the six months ended June 30, is due by August 14, 2026 under the standard 45-day reporting deadline.

Daewoong Pharmaceutical released preliminary Q2 2026 results on 29 July, ahead of its 14 August H1 statutory-report deadline.

Peptron is due to file its 2026 first-half report by August 14, 2026, providing the next scheduled company financial and operating update before September 7.

Kolon Life Science is expected to file its 2026 half-year report on 14 August, based on its established DART reporting cadence; the company has not announced a separate earnings-release notice.

LigaChem Biosciences’ 2026 half-year report is due by August 14, 2026 under the Korean disclosure schedule for December fiscal-year issuers.

Alteogen’s statutory 2026 H1 semiannual report remains due on August 14 after it released preliminary Q2 and H1 results on August 7.

OliX is expected to release its second-quarter 2026 financial results on August 14, 2026.

ABL Bio's statutory deadline to file its H1 2026 semiannual report is August 14, 2026.

Voronoi is due to file its 2026 first-half semiannual report by August 14, 2026.

AprilBio is due to file its 2026 half-year report, containing second-quarter financial results, by August 14.

HK inno.N scheduled an extraordinary shareholders’ meeting for August 12, 2026 to elect Jang In-jin as an independent director.

BlackRock Fund Advisors disclosed that its passive managed stake in Yuhan increased to 4,785,125 shares, or 6.50%, as of July 31, 2026, from 5.07%.

LigaChem’s finalized LNCB74 rights agreement carries confidential milestones and royalties whose total potential value exceeds 10% of its 2025 consolidated equity.

BlackRock Fund Advisors disclosed a new 5.03% passive holding in Alteogen as of July 31, 2026.

Voronoi added Canada to the planned global Phase 1/2 expansion of VRN110755 after its CRO confirmed submission of the clinical-trial application to Health Canada on August 7.

Alteogen’s August 5 ALT-B4 license remains pending upfront-payment confirmation, while the August 7 results indicate that the agreement was not part of reported H1 licensing revenue.

SK Biopharmaceuticals reported Q2 2026 revenue of KRW 247.4 billion and operating profit of KRW 97.1 billion, while XCOPRI U.S. sales reached $149.5 million and full-year sales guidance of $550–580 million was maintained.

OliX extended the outside date for its Key2Brain CNS-delivery technology evaluation and option agreement from March 31, 2027 to December 31, 2027 following an adjustment to the detailed experimental schedule.